Bulletin
Investor Alert

AbbVie Inc.

NYS: ABBV

GO
/marketstate/country/us

After Hours

/zigman2/quotes/202428675/composite

$

87.09

Change

+0.20 +0.23%

Volume

Volume 136,013

Sep 29, 2020, 7:59 p.m.

Real time quotes

/zigman2/quotes/202428675/composite

Today's close

$ 87.28

$ 86.89

Change

-0.39 -0.45%

Day low

Day high

$86.31

$87.28

Open
Open: 87.11

52 week low

52 week high

$62.55

$101.28

Open

Market cap

$154.03B

Average volume

7.09M

P/E ratio

18.48

Rev. per Employee

$1.09M

EPS

4.70

Dividend

1.18

Div yield

5.43%

Ex dividend date

10/14/20

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/abbv

MarketWatch News on ABBV

  1. Moderna Inc. stock outperforms market despite losses on the day

    4:25 p.m. Today

    - MarketWatch Automation

  2. Moderna Inc. stock rises Monday, still underperforms market

    4:52 p.m. Sept. 28, 2020

    - MarketWatch Automation

  3. The Pandemic Speeds Up the Health-Care Revolution

    8:56 a.m. Sept. 28, 2020

    - Lauren R. Rublin

  4. General Motors and 9 Other Big-Cap Stocks Worth a Look

    8:59 a.m. Sept. 22, 2020

    - Andrew Bary

  5. Philip Morris and American Tower Boost Their Dividends

    8:30 a.m. Sept. 12, 2020

    - Lawrence C. Strauss

  6. U.S. Drug Stocks Are Cheap Relative to the S&P 500

    10:20 a.m. Sept. 11, 2020

    - Andrew Bary

  7. Investors Are Betting Big on a Covid-19 Vaccine. Is That Safe?

    7:44 a.m. Aug. 31, 2020

    - Josh Nathan-Kazis

  8. 5 New Stocks That Are Hedge Funds’ Favorites

    3:44 p.m. Aug. 21, 2020

    - Carleton English

  9. Don’t Just Focus on Pfizer’s Covid Vaccine, Analyst Says

    11:11 a.m. Aug. 20, 2020

    - Shaina Mishkin

  10. FDA Rejects Potential Gilead Blockbusters, Scrambling Drug Stocks

    10:42 a.m. Aug. 19, 2020

    - Josh Nathan-Kazis

  11. Buy Merck for Its Unappreciated Pipeline, Says Goldman

    10:47 a.m. Aug. 3, 2020

    - Bill Alpert

  12. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/abbv

Other News on ABBV

  1. AbbVie Elezanumab Gets FDA's Fast Track and Orphan Drug Tags

    10:52 a.m. Today

    - Zacks.com

  2. Myovant slumps 20% on disappointing relugolix data in prostate cancer

    9:21 a.m. Today

    - Seeking Alpha

  3. Pfizer's (PFE) Xeljanz Gets FDA Approval for 4th Indication

    7:10 a.m. Today

    - Zacks.com

  4. What's Wrong with Dividend-Income Stocks (MO, ABBV)

    6:44 a.m. Today

    - Baystreet.ca

  5. AbbVie (ABBV) Gains But Lags Market: What You Should Know

    5:45 p.m. Sept. 28, 2020

    - Zacks.com

  6. Motorhome Retirement: August Update - Family Time

    3:53 p.m. Sept. 28, 2020

    - Seeking Alpha

  7. Gilead & Galapagos' RA Drug Receives Approval in Europe

    3:01 p.m. Sept. 28, 2020

    - Zacks.com

  8. 7 Sin Stocks To Buy That Will Outperform the S&P 500

    2:19 p.m. Sept. 25, 2020

    - InvestorPlace.com

  9. FDA issues final rule for importation of drugs from abroad

    7:21 a.m. Sept. 25, 2020

    - Seeking Alpha

  10. 56 Outstanding Dividend Stocks For October From Kiplinger

    11:41 p.m. Sept. 24, 2020

    - Seeking Alpha

  11. Aerie' Roclanda on par with Allergan's Ganfort in glaucoma study

    7:32 a.m. Sept. 24, 2020

    - Seeking Alpha

  12. 4 Dividend Growth Opportunities To Benefit From Market Decline

    11:42 a.m. Sept. 23, 2020

    - Seeking Alpha

  13. PEY Yourself More Or Lower Your Volatility With SPHD?

    7:44 a.m. Sept. 23, 2020

    - Seeking Alpha

  14. Loading more headlines...
/news/pressrelease/company/us/abbv

Press Releases on ABBV

  1. What's Wrong with Dividend-Income Stocks (MO, ABBV)

    6:45 a.m. Today

    - Baystreet.ca

  2. Axial Spondyloarthritis Market Latest Advancements and Global Research Report 2020 to 2030

    1:37 a.m. Today

    - Market Insight Reports

  3. 5 Social Media Stocks Poised for Post-Pandemic Success

    9:26 a.m. Sept. 28, 2020

    - IAM Newswire

  4. Loading more headlines...

Rates »

Link to MarketWatch's Slice.